AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06240455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WP1302 placebo
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study NCT06240455 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study NCT05032235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
Study NCT04155099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX7455
Description: RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
Study NCT04155099 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with cellulose filler
Study NCT05908448 — intervention group
Intervention type: DEVICE
Intervention: 13 CGM (continuous glucose monitor)
Description: The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
Study NCT06240455 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: methimazole
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study NCT06441305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWITCH intervention package
Description: * Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up.
Study NCT06635642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dichotic Interaural Intensity Difference (DIID) Training
Description: A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
Study NCT06510231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
Study NCT06510231 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
Study NCT04539873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
Study NCT04539873 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL GROUP
Description: In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
Study NCT05924100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injection [Reblozyl]
Description: Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit.
Study NCT05338853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gongs mobilization
Description: to deal adhesive capsulitis
Study NCT05338853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular mobilization
Description: scapular mobilization
Study NCT05740215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
Study NCT05740215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules
Study NCT06458751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: electrophysiological study
Description: Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
Study NCT06458751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: electromyograph
Description: surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
Study NCT05188417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban 0.05 MG/ML
Description: intravenous injection of the drug according to different body weights and arms
Study NCT05188417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: intravenous injection of the drug according to different body weights and arms
Study NCT04973800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: Simvastatin 20mg ON PO for 28-30 days
Study NCT04973800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose placebo ON PO for 28-30 days
Study NCT06162507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study NCT04768062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Description: Received during weekly intravenous infusions
Study NCT06476899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: orelabrutinib tablets
Study NCT06476899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR/BR
Description: FCR/BR
Study NCT06476899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTK inhibitor
Description: BTK inhibitor choose by physican
Study NCT06392607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology (standard coating)
Description: Lens with the current coating
Study NCT01171079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of oxidized regenerated cellulose
Study NCT06392607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology (enhanced coating)
Description: Lens with the enhanced coating
Study NCT06351020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
Study NCT06351020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: The subjects will receive Apatinib orally,qd
Study NCT06351020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
Study NCT04514133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participating in Action Civics program
Description: Students in school classrooms participating in Action Civics program
Study NCT06080958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT
Description: the NPWT dressing applied to fasciocutaneous flap
Study NCT06080958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional dressing
Description: Conventional dressing ( topical care ) applied to fasciocutaneous flap
Study NCT04259762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast, Colorectal, and Cervical Cancer Screening Interventions
Description: Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
Study NCT05369676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 1/Ritonavir
Description: Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
Study NCT05369676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 dose 2/Ritonavir
Description: Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
Study NCT04845893 — intervention group
Intervention type: OTHER
Intervention: Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
Study NCT06142630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteration of patients' position after erector spinae plane block
Description: After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
Study NCT06269211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IV, Q3W
Study NCT05555771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
Study NCT06649383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
Study NCT05555771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
Study NCT05067673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
Study NCT05067673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dry needling
Description: Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
Study NCT04925180 — intervention group
Intervention type: DRUG
Intervention: Cyproterone Acetate (Androcur, BAY94-8367)
Description: As prescribed by the treating physician
Study NCT04759339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
Study NCT05090423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training alone
Description: The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller.
Study NCT05927701 — intervention group
Intervention type: OTHER
Intervention: Group comparaison
Description: Questionnaires
Study NCT05642078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine(0.25ml/vial)
Description: Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
Study NCT05642078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine(0.5ml/vial)
Description: Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
Study NCT05642078 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active compared Vaccine
Description: Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
Study NCT05090423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training and neurodynamic intervention for the common peroneal nerve
Description: The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller.
Study NCT04816682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
Study NCT06317441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention consists of a probiotic either with a low or high dosage
Study NCT01549470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
Study NCT01549470 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
Study NCT04851067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Therapeutic Exercises (DNTEx)
Description: Already included in arm/group descriptions.
Study NCT04851067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Therapeutic Exercises (MTTEx)
Description: Already included in arm/group descriptions.
Study NCT04194346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
Study NCT06290765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value.
Study NCT06290765 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy and aspirin
Description: Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
Study NCT06290765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy and aspirin
Description: Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.